Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on G-CSF (Jun 2017)

Posted by Matt Breese on Jun 16, 2017

Find me on:

According to our recent payer coverage analysis for G-CSF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

Note from the Editor: due to the importance of medical benefit for G-CSF, we've updated this reality check to include a snapshot of market access across medical benefit.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for G-CSF products over the past quarter shows some minor shifts across payer channels. Health exchange formularies feature the greatest percentage of lives restricted by a PA or step edit.


Data snapshot as of Q2 2017 

Trends: The number of biosimilar entrants on the horizon could create some significant shifts in market access and prescribing habits. A recent international study does show an adjusted prescriber attitude towards lower cost G-CSF treatments when relevant clinical and regulatory substantiation is present.

To read the full Reality Check on G-CSF treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check


Topics: Specialty, Market Access, Payer, Branding & Marketing